跳到正文
做药的那些个事· Kevin·· 10 天前AI 评分69

FDA 向美国药厂 Victory Medical 发出 483,列层流罩密封胶、无菌操作与环境监测缺陷

从FDA检查一家美国药厂所出的483看HEPA清洁维护的细节要求

AI 导读

FDA 于 2026 年 8 月检查美国药厂 Victory Medical 后发布的 483 列出层流罩密封胶、无菌操作及环境监测等多项缺陷。文章译出观察项 2、3、4、7、8、9,包括 ISO 5 层流罩内 HEPA 过滤器框架密封胶涂布不均、粗糙多孔、变色老化并与框架分离。

正文

本篇内容取自FDA于2026年08月检查美国一家药厂(Victory Medical)后所发布的483的部分内容。重点关注无菌生产区域的清洁消毒、环境监测相关的问题。

OBSERVATION 2

Production areas have difficult to clean or contain porous, particle generating, or visibly dirty equipment or surfaces.

生产区域存在难以清洁的设备或表面,或存在多孔、易产生颗粒、或明显脏污的设备或表面。

Specifically, on August 31, 2026, the following deficiencies were observed on your firm's [REDACTED] ISO 5 [REDACTED] Laminar Airflow Hood: Caulking material was observed applied along the frame edges of the HEPA filter housing within your firm's [REDACTED] ISO 5 [REDACTED] Laminar Airflow Hood (LAFH). The caulking exhibited the following defects:

公司ISO 5 级层流罩(LAFH)内,观察到 HEPA 高效过滤器框架边缘打有密封胶。该密封胶存在以下缺陷:

•Uneven and irregular application — The caulking was applied unevenly along the frame seams, resulting in inconsistent thickness and width, with visible ridges, valleys, and surface irregularities. These surface irregularities cannot be adequately cleaned or disinfected and provide sites where microbial contamination, cleaning solution residue, and particulate matter can accumulate and persist despite cleaning efforts.

•涂布不均、形状不规则——密封胶沿框架接缝涂抹不均,厚度与宽度不一致,可见凸脊、凹陷及表面凹凸不平。这些表面不平整处无法被充分清洁或消毒。

•Rough and porous surface texture — The caulking surface was visibly rough and non-smooth in texture. A porous, rough surface within an ISO 5 critical zone is inherently incompatible with the cleanliness requirements of a sterile environment, as it cannot be effectively wiped down or disinfected and can harbor microbial contamination within its surface irregularities.

•表面粗糙、多孔——密封胶表面肉眼可见粗糙、不平滑,无法被有效擦拭或消毒,且可在表面凹凸处藏匿微生物污染。

•Discoloration and signs of degradation — The caulking exhibited visible discoloration and signs of aging and chemical degradation, consistent with prolonged exposure to cleaning and disinfecting agents. Degraded caulking material is prone to cracking, flaking, and shedding, generating particles that can directly contaminate the critical production area and the sterile drug products prepared within it.

•变色及劣化迹象——密封胶可见变色,并呈现老化与化学降解迹象。已劣化的密封胶材料易开裂、起皮和脱落,产生颗粒。

•Separation and cracking from the frame surface — The caulking appeared to be pulling away from and separating from the frame surface in areas, creating open crevices that cannot be cleaned or disinfected and that serve as harborage points for microbial contamination and a source of particle generation within the ISO 5 environment.

•与框架表面分离、开裂——密封胶在部分区域似已脱离并离开框架表面,形成无法清洁或消毒的开放缝隙。

OBSERVATION 3 

Personnel were observed manually contacting the inner surface of a sterile container or closure.

观察到人员用手直接接触无菌容器或密封件的内表面。

Specifically, the following observations were made:

1)During the aseptic production on August 31, 2026 of ELECTRO B COMPLEX (MDV) MAGNESIUM CHLORIDE/CALCIUM CHLORIDE/B COMPLEX/SODIUM BICARBONATE (105MG/28MG/B-COMPLEX,12MG/ML) STOCK SOLUTION, Lot 2055939, BUD October 20, 2026, the following aseptic processing techniques were directly observed:

1)2026 年 8 月 31 日无菌生产 ELECTRO B COMPLEX(MDV)氯化镁/氯化钙/B 族复合维生素/碳酸氢钠(105mg/28mg/B 族复合维生素,12mg/mL)母液(批号 2055939,使用期限 2026 年 10 月 20 日)过程中,直接观察到以下无菌操作行为:

•Your firm's sterile technician was observed reaching into a bag of rubber stoppers with a gloved hand to retrieve individual stoppers for placement onto vials. During this retrieval, the sterile technician was observed directly touching the inner surface (product contact area) of the rubber stoppers with their gloved hand.

•观察到贵公司无菌操作人员将戴手套的手伸入盛装胶塞的袋中,逐只取塞以便加在西林瓶上。在取塞过程中,观察到该无菌操作人员用手套直接接触胶塞内表面。

•Your firm's sterile technician was observed pouring rubber stoppers directly from the bag onto the surface of the work bench and then using a gloved hand to retrieve individual stoppers from the bench surface for placement onto vials.

•观察到公司无菌操作人员将胶塞直接从袋中倒在操作台面上,随后用戴手套的手从台面上逐只取塞,以便放置到西林瓶上。

2)On September 1, 2026, during the aseptic production of TIRZEPATIDE/L-CARNITINE (25/50MG/ML) STOCK SOLUTION, Lot 2057705, BUD November 1, 2026, your firm's sterile technician was observed reaching into a bag containing syringes used for filling with a gloved hand. The syringes were not oriented within the bag in a manner that would prevent direct contact with the product contact surfaces of the syringes during retrieval.

2)2026 年 9 月 1 日,在无菌配制 TIRZEPATIDE(替尔泊肽)/L-CARNITINE(左卡尼汀)(25/50mg/mL)母液(批号 2057705,使用期限 2026 年 11 月 1 日)过程中,观察到贵公司无菌操作人员将戴手套的手伸入盛装灌装用注射器的袋中。袋内注射器的摆放方向不足以在取用时避免直接接触注射器的产品接触面。

OBSERVATION 4

The facility design was observed to allow the influx of lesser quality air into a classified area containing higher quality air.

观察到厂房设计允许质量较低的空气流入洁净度较高的洁净区。

Specifically,

具体而言:

•Your firm's [REDACTED] ISO 5 [REDACTED] Laminar Airflow Hood (LAFH) is designed in a manner that potentially exposes sterile drug products and sterile containers/closures to air of a lower than ISO 5 classification. For example, I observed an air intake vent is located directly behind the sterile technician's working area inside of the ISO 5 LAFH. This vent has not been monitored for unidirectional airflow and is not included in your firm's [REDACTED] environmental monitoring sampling program.

•观察到在 ISO 5 层流罩内部,进风口正位于无菌操作人员操作区的后方。该进风口未进行单向流的监测,也未纳入贵公司环境监测取样计划。

•I observed that your firm's [REDACTED] connecting the unclassified space to the ISO 8 buffer room lacks a HEPA filter. This design allows unfiltered, lower-quality air from the unclassified space to enter the ISO 8 ante room.

•贵公司连接非洁净区与 ISO 8 缓冲间的区域未安装 HEPA 过滤器。该设计使非洁净区未经过滤、质量较低的空气可进入 ISO 8 前室。

OBSERVATION 7

Failure to appropriately and regularly clean and disinfect or sterilize equipment located in the ISO 5 area.

未对位于 ISO 5 区域的设备进行适当、定期的清洁、消毒或灭菌。

Specifically, the following deficiencies were observed:

具体发现以下缺陷:

•The sterile technician failed to clean the sides and back surfaces of the [REDACTED] located inside of the ISO 5 LAFH.

•无菌操作人员未清洁位于 ISO 5 层流罩内部的侧面和后部表面。

•The sterile technician failed to clean in between the grates of the vent located [REDACTED] the [REDACTED]

•无菌操作人员未清洁位于通风口格栅之间的部位。

OBSERVATION 8

Lack of routine environmental monitoring in the ISO 5 area and classified areas.

ISO 5 区域及各洁净区缺乏例行环境监测。

Specifically, the following deficiencies were observed:

1)Absence of Historical Surface Sampling Data — Your firm was unable to provide surface sampling environmental monitoring data for your ISO 5 Laminar Airflow Hood (LAFH) and classified cleanrooms prior to July 29, 2026.

1)缺少历史表面取样数据——贵公司无法提供 2026 年 7 月 29 日之前 ISO 5 级层流罩(LAFH)及各洁净室的表面取样环境监测数据。

2)Inadequate Surface Sampling of the ISO 5 LAFH — Insufficient Sampling Locations — According to your firm's personnel and the hood recertification records, only one location within the ISO 5 Laminar Airflow Hood is sampled during surface sampling.

2)ISO 5 层流罩表面取样不充分——取样点不足——据贵公司人员及层流罩再确认记录,表面取样时仅在 ISO 5 级层流罩内的一个位置取样。

3)Failure to Monitor the [REDACTED]. Your firm does not perform surface sampling environmental monitoring of the [REDACTED] connecting the unclassified laboratory area to the ISO 8 ante room.

3)未对连接非洁净检验区与 ISO 8 前室的区域开展表面取样环境监测。

OBSERVATION 9

Sterile drugs and Materials were exposed to lower than ISO 5 quality air.

无菌药品及物料暴露于低于 ISO 5 级的空气中。

Specifically, sterile wipes used to disinfect your firm's [REDACTED] ISO 5 [REDACTED] Laminar Airflow Hood (LAFH) were staged open and exposed to lower than ISO 5 quality air prior to use. On August 31, 2026, sterile wipes were observed staged open and exposed on a [REDACTED] located in the ISO 7 cleanroom. These wipes were subsequently used to disinfect the firm's [REDACTED] ISO 5 [REDACTED] LAFH. According to firm personnel, sterile wipes are regularly removed from their packaging and stored open in the ISO 7 cleanroom prior to being used to disinfect the ISO 5 LAFH.

用于消毒贵ISO 5 级层流罩(LAFH)的无菌擦拭布,在使用前被敞开摆放并暴露于低于 ISO 5 级的空气中。2026 年 8 月 31 日,观察到无菌擦拭布在 ISO 7 洁净室内敞开摆放、处于暴露状态。这些擦拭布随后被用于消毒贵公司ISO 5 级层流罩。据公司人员称,无菌擦拭布通常会从原包装中取出,敞开存放于 ISO 7 洁净室,然后再用于消毒 ISO 5 层流罩。

来源:做药的那些个事 · mp.weixin.qq.com